By Tempus AILearning Objectives
- Understand what Tempus AI does and how clinical AI improves cancer treatment decisions
- Evaluate Tempus's data platform, genomic testing, and AI software capabilities
- Assess Tempus's business model combining diagnostics revenue with data licensing
What Is Tempus AI?
Tempus AI (NASDAQ: TEM) is a clinical AI and precision medicine company that helps oncologists select the most effective targeted therapies for individual cancer patients. The platform combines genomic testing (analyzing a patient's tumor DNA), AI software (interpreting results and recommending treatments), and the largest multimodal clinical dataset in the industry — 40+ million records connected via 4,500+ integrations.
With $1.27 billion in 2025 revenue (+83% year-over-year) and an $8.9 billion market cap, Tempus is one of the largest AI healthcare companies.
Key Products
| Product | What It Does |
|---|---|
| xT (Tumor DNA) | Comprehensive genomic profiling from solid tumor tissue |
| xF (Liquid Biopsy) | Blood-based cancer detection and monitoring |
| xR (RNA) | RNA sequencing for treatment selection |
| Tempus One | Generative AI clinical assistant integrated into EHR systems |
| Tempus Next | Care pathway intelligence platform (expanded to breast cancer 2025) |
| Tempus xM | Liquid biopsy for minimal residual disease and immunotherapy response |
Company Details
| Detail | Info |
|---|---|
| Company | Tempus AI Inc. (NASDAQ: TEM) |
| CEO | Eric Lefkofsky (co-founder) |
| Headquarters | Chicago, Illinois |
| IPO | June 2024 |
| Revenue (2025) | $1.27 billion (+83% year-over-year) |
| Market Cap | ~$8.9 billion |
| Clinical Records | 40+ million connected via 4,500+ integrations |
| Website | tempus.com |
Key Takeaways
- Tempus combines genomic testing, AI software, and the largest clinical dataset (40+ million records) to help oncologists choose the most effective cancer treatments
- $1.27 billion revenue growing 83%; uniquely positioned at the intersection of diagnostics and AI data licensing
- Competes with Foundation Medicine (Roche), Guardant Health, and Illumina in genomics; unique in combining testing revenue with data platform
